Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | APAF1 | O14727 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929254 | 0.90 | CA12 (0.39) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8057064 | 0.75 | CA12 (0.53) | CA12CA1CA2CA9LMNA | |
| SCHEMBL4778070 | 0.75 | CA12 (0.53) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8406469 | 0.74 | LMNA (0.54) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8663705 | 0.74 | LMNA (0.51) | CA12CA1CA2CA9LMNA | |
| SCHEMBL4776717 | 0.73 | CA12 (0.53) | CA12CA1CA2CA9LMNA | |
| SCHEMBL7738661 | 0.71 | CA12 (0.51) | CA12CA1CA2CA9LMNA | |
| SCHEMBL14759752 | 0.71 | TTR (0.50) | CA12CA1CA2CA9MAPT | |
| SCHEMBL461642 | 0.70 | CA12 (0.61) | CA12CA1CA2CA9LMNA | |
| SCHEMBL31121933 | 0.70 | CA12 (0.61) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3864122-A1 | CLEANING COMPOSITIONS AND USES THEREOF | Novozymes A/S (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| WO-2013062885-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012087788-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087793-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087785-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087790-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087787-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087792-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087789-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087786-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | CA12 3748/4885CA1 4656/4885CA2 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.